Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2017-08-29 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
第一届监事会第八次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Shenzhen BGI Genomics Co., Ltd. It details the decisions made during the eighth meeting of the first Supervisory Board, including approval of the 2017 semi-annual report, use of raised funds, accounting policy changes, and amendments to meeting rules. The document does not contain the full semi-annual report or detailed financial statements but references that the full report and other detailed announcements are available on the official disclosure website. The document is relatively short (2460 characters) and serves as an official meeting resolution announcement rather than a full financial report or detailed management discussion. It also includes governance-related decisions but is primarily a meeting resolution announcement. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution disclosure, not as the semi-annual report itself or a management report.
2017-08-29 Chinese
关于使用暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen BGI Genomics Co., Ltd. regarding the use of temporarily idle raised funds for cash management by purchasing low-risk bank wealth management products. It details the approval by the board and supervisory committee, investment purpose, risk analysis, and compliance with regulatory requirements. The document references the approval by the China Securities Regulatory Commission for the IPO and the use of raised funds, but it is not a financial report itself. It is a regulatory announcement about the use of raised funds, not a full financial report or audit. The document length is 3547 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this fits best under Capital/Financing Update (CAP) as it concerns the management and use of capital raised through financing activities.
2017-08-11 Chinese
验资报告（2017年7月11日）
Regulatory Filings
2017-08-11 Chinese
中信证券股份有限公司关于公司使用闲置募集资金进行现金管理事项的核查意见
Regulatory Filings
2017-08-11 Chinese
关于签订募集资金三方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a tripartite supervision agreement for raised funds by Shenzhen BGI Co., Ltd. It details the amount of funds raised, the opening of special accounts for these funds, and the terms of the supervision agreement involving the company, banks, and the sponsoring institution. The document includes references to regulatory approvals and an audit report but does not contain actual financial statements or detailed financial performance data. The length is about 2500 characters, which is relatively short and consistent with an announcement rather than a full report. The content focuses on fundraising and regulatory compliance related to the use of raised capital, which aligns with a Capital/Financing Update. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2017-08-11 Chinese
第一届监事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution passed at the seventh meeting of the first Supervisory Board of Shenzhen BGI Genomics Co., Ltd. It details the meeting's convening, attendance, and the approval of a proposal regarding the use of temporarily idle raised funds for cash management. The document includes voting results and references compliance with relevant laws and company regulations. It does not contain financial statements or detailed financial data, nor is it a full report or presentation. The document is an official announcement of a board/management decision related to fund usage and governance. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear meeting resolution content and voting results.
2017-08-11 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.